Iovance Biotherapeutics, Inc. (IOVA) Stock Forecast
IOVA analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.40 / 5 from 10 analysts
- Price target
- $14.40 average of analyst targets
- Upside to target
- +5.7% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.09
- 52-week range
- $1.81 – $14.82
IOVA analyst ratings
10 analystsNumber of analysts at each rating.
IOVA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IOVA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.09 | −$0.10 | −$0.07 | −$0.25 | +65.9% | 8 |
| Current fiscal year (2026) | −$0.45 | −$0.50 | −$0.41 | −$1.09 | +58.6% | 8 |
| Next fiscal year (2027) | −$0.20 | −$0.42 | −$0.10 | −$0.45 | +56.6% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IOVA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $115.0M | $109.7M | $118.4M | +70.5% | 7 |
| Current fiscal year (2026) | $412.7M | $404.6M | $418.3M | +56.6% | 7 |
| Next fiscal year (2027) | $593.6M | $564.4M | $659.0M | +43.8% | 9 |
IOVA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IOVA revenue: reported and forecast
IOVA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.12 | −$0.09 | −$0.10 | −$0.09 | −$0.09 | −31.5% | 2 up · 0 down |
| Current fiscal year (2026) | −$0.56 | −$0.48 | −$0.50 | −$0.46 | −$0.45 | −20.1% | 5 up · 0 down |
| Next fiscal year (2027) | −$0.32 | −$0.27 | −$0.29 | −$0.24 | −$0.20 | −38.6% | 5 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IOVA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IOVA beat in 8 of 12.
What analysts expect from IOVA
10 analysts cover Iovance Biotherapeutics; their consensus rating is buy (4.40 on a 1–5 scale, where 5 is a strong buy). The average price target is $14.40, 5.7% above the latest close of $13.62. Analysts expect earnings of −$0.45 per share for 2026, +58.6% from a year earlier. For 2027 the average estimate is −$0.20 per share on revenue of $593.6 million. Iovance Biotherapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: IOVA income statement, IOVA key metrics, IOVA chart. See the IOVA stock overview for the latest quote and news.
IOVA forecast FAQ
What is Iovance Biotherapeutics's price target?
The average analyst price target for Iovance Biotherapeutics is $14.40, 5.7% above the latest close of $13.62.
Is Iovance Biotherapeutics a buy, hold or sell?
Of 10 analysts covering Iovance Biotherapeutics, 6 rate it a strong buy, 2 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Iovance Biotherapeutics's EPS forecast?
Analysts forecast −$0.45 per share for 2026 (range −$0.50 to −$0.41); for 2027 the estimate is −$0.20.
What is Iovance Biotherapeutics's revenue forecast?
The average revenue estimate for 2026 is $412.7 million, growth of 56.6%; for 2027 it is $593.6 million.
When does Iovance Biotherapeutics report earnings?
Iovance Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.09.
Does Iovance Biotherapeutics usually beat earnings estimates?
Iovance Biotherapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.